Iradimed (NASDAQ: IRMD) CFO John Glenn reports stock sales and RSU vesting

Rhea-AI Filing Summary

Iradimed Corporation’s chief financial officer, John Glenn, reported several personal stock transactions in the company’s common shares on December 11, 2025. He sold 14,468 shares at a weighted average price of $97.26 in multiple trades and an additional 532 shares at $98.09, as part of his ongoing equity activity.

On the same date, 1,812 restricted stock units (RSUs) converted into common stock on a one‑for‑one basis, and 714 shares were withheld at $97.38 to cover tax obligations, leaving him with 8,460 shares of common stock held directly. He also beneficially owns 3,624 RSUs granted under Iradimed’s 2023 Equity Incentive Plan, which vest in three equal annual installments beginning on December 11, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GLENN JOHN

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		S		14,468	D	$97.26(1)	7,894	D
Common Stock	12/11/2025		S		532	D	$98.09	7,362	D
Common Stock	12/11/2025		M		1,812(2)	A	(2)	9,174	D
Common Stock	12/11/2025		F		714	D	$97.38	8,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	12/11/2025		M			1,812	(3)	(3)	Common Stock	1,812	$0	3,624	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $97.00 to $97.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. Restricted stock units convert into common stock on a one-for-one basis.

3. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

	/s/ John Glenn	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Iradimed (IRMD) report for its CFO on December 11, 2025?

Iradimed (IRMD) reported that its chief financial officer, John Glenn, conducted multiple transactions on December 11, 2025, including open-market sales of common stock, the conversion of restricted stock units (RSUs) into shares, and a share withholding to cover taxes related to equity vesting.

How many Iradimed (IRMD) shares did CFO John Glenn sell, and at what prices?

John Glenn sold 14,468 shares of Iradimed common stock at a weighted average price of $97.26 in multiple trades, and an additional 532 shares at $98.09. The larger transaction was executed in multiple trades between $97.00 and $97.85, with the weighted average of $97.26 reported.

What restricted stock unit (RSU) activity did Iradimed’s CFO report in this filing?

On December 11, 2025, 1,812 RSUs held by John Glenn converted into Iradimed common stock on a one-for-one basis. These RSUs were granted under Iradimed Corporation’s 2023 Equity Incentive Plan and are part of a broader RSU award that vests over time.

How many Iradimed (IRMD) shares and RSUs does John Glenn own after the reported transactions?

Following the reported transactions, John Glenn beneficially owns 8,460 shares of Iradimed common stock directly. He also beneficially owns 3,624 restricted stock units, which represent the right to receive an equivalent number of shares upon vesting.

How do the Iradimed 2023 Equity Incentive Plan RSUs for the CFO vest?

The RSUs granted to John Glenn under Iradimed Corporation’s 2023 Equity Incentive Plan vest in three equal annual installments beginning on December 11, 2025. Upon each vesting date, he will receive a number of shares of common stock equal to the number of RSUs that have vested.

Why were 714 Iradimed shares reported with transaction code "F" in this Form 4?

The filing shows a transaction of 714 shares with code "F", indicating shares were disposed of to satisfy tax withholding obligations related to equity vesting. These shares were withheld at a price of $97.38, and the transaction reduced the number of shares held directly while covering the associated tax liability.